{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:02:55Z","timestamp":1771930975859,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate-specific antigen velocity (PSAV) has emerged as a promising biomarker for predicting survival outcomes in prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the association between PSAV and both all-cause mortality and prostate cancer-specific mortality (PCSM) in men diagnosed with prostate cancer by conducting a meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive search of electronic medical databases, including PubMed, Web of Science, and Embase, was conducted to identify relevant studies published up to March 1, 2025. Studies reporting adjusted hazard ratios (HR) with 95% confidence intervals (CI) for survival outcomes in prostate cancer patients, based on categorical analyses of PSAV, were included. Pooled HRs with 95% CI was calculated using random-effects models to account for clinical heterogeneity across studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Eleven studies involving 3,713 prostate cancer patients were identified and analyzed. The meta-analysis revealed that elevated PSAV was associated with a higher risk of both all-cause mortality (HR 1.96; 95% CI 1.33\u20132.88) and PCSM (HR 5.38; 95% CI 2.76\u201310.51). In stratified analyses, the pooled HR for all-cause mortality was 1.91 (95% CI 1.43\u20132.55) among patients with localized prostate cancer, compared to 1.26 (95% CI 0.41\u20133.84) in those with metastatic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated PSAV is a significant predictor of all-cause mortality and PCSM in prostate cancer patients. Measuring PSAV has the potential to improve the prediction of survival outcomes in this population. However, further research is needed to standardize PSAV measurement and validate its predictive value across diverse patient groups. Systematic review registration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1656688","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T05:30:34Z","timestamp":1770701434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate-specific antigen velocity as a predictor of survival outcomes in patients with prostate cancer: a meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Feilun","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Jiangsu University","place":["Zhenjiang, China"]},{"name":"Department of Urology, Affiliated Taizhou Second People\u2019s Hospital of Yangzhou University","place":["Taizhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueshi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science, Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science, Liaoning University of Traditional Chinese Medicine","place":["Shenyang, Liaoning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cancer Institute, The Affiliated People\u2019s Hospital, Jiangsu University","place":["Zhenjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changfeng","family":"Man","sequence":"additional","affiliation":[{"name":"Cancer Institute, The Affiliated People\u2019s Hospital, Jiangsu University","place":["Zhenjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Fan","sequence":"additional","affiliation":[{"name":"Cancer Institute, The Affiliated People\u2019s Hospital, Jiangsu University","place":["Zhenjiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/17562872221103988","article-title":"Biomarkers for prostate cancer detection and risk stratification","volume":"14","author":"Farha","year":"2022","journal-title":"Ther Adv Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113400","article-title":"The association between prostate-specific antigen velocity (PSAV), value and acceleration, and of the free PSA\/total PSA index or ratio, with prostate conditions","volume":"9","author":"Flores-Fraile","year":"2020","journal-title":"J Clin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.04.010","article-title":"PSA velocity: a systematic review of clinical applications","volume":"32","author":"Loughlin","year":"2014","journal-title":"Urol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000181209.37013.99","article-title":"Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy","volume":"174","author":"Sengupta","year":"2005","journal-title":"J Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032975","article-title":"Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy","volume":"351","author":"D\u2019Amico","year":"2004","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.4.440","article-title":"Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy","volume":"294","author":"D\u2019Amico","year":"2005","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24526","article-title":"Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE","volume":"115","author":"Abouassaly","year":"2009","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e219452","DOI":"10.1001\/jamanetworkopen.2021.9452","article-title":"Association of prostate-specific antigen velocity with clinical progression among african american and non-hispanic white men treated for low-risk prostate cancer with active surveillanc","volume":"4","author":"Nelson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21576","article-title":"Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma","volume":"106","author":"Rozhansky","year":"2006","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23388","article-title":"Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy","volume":"112","author":"Palma","year":"2008","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40779-021-00364-x","article-title":"Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate","volume":"9","author":"Wang","year":"2022","journal-title":"Mil Med Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"B17","unstructured":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses\n          \n          \n            \n              Wells\n              G\n            \n            \n              Shea\n              B\n            \n            \n              O\u2019Connell\n              D\n            \n            \n              Peterson\n              J\n            \n            \n              Welch\n              V\n            \n            \n              Losos\n              M"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.04.035","article-title":"Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy","volume":"70","author":"Daskivich","year":"2007","journal-title":"Urology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0529-5815.2009.22.009","article-title":"The survival analysis of the metastatic castration-resistant prostate cancer","volume":"47","author":"Ma","year":"2009","journal-title":"Chin J Surg"},{"key":"B22","article-title":"Relationship of preoperative PSA velocity to histopathological findings in the surgical specimen and survival after radical prostatectomy","volume":"34","author":"Rodr\u00edguez-Alonso","year":"2010","journal-title":"Actas Urol Esp"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.03.030","article-title":"Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death","volume":"107","author":"Shi","year":"2013","journal-title":"Radiother Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/pcan.2014.44","article-title":"Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials","volume":"18","author":"Suzman","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.132","article-title":"Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase","volume":"179","author":"Robinson","year":"2008","journal-title":"J Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13944","article-title":"Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study)","volume":"20","author":"Chua","year":"2024","journal-title":"Asia Pac J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2021.06.673","article-title":"Role of PSA kinetics in hormone-refractory prostate cancer","volume":"31","author":"Sabur","year":"2021","journal-title":"J Coll Physicians Surg Pak"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1656688\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:00:28Z","timestamp":1771927228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1656688\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1656688"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1656688","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"1656688"}}